drugset / Trial / NCT02074163

ASIS for Botox in Chronic Migraine

NCT02074163

Phase 1/2 Unknown 60 enrolled ASIS Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

Botox acts on nerve endings, yet there are no nerve endings inside the muscle, where they are typically injected. All nerves terminate on the fascia, where ASIS device can precisely deliver Botox by creating that subdermal bloodless space, between the skin and muscle. Thus enhancing and prolonging Botox's efficacy, at the same time prevent it's unnecessary adverse reactions and distant spread, especially since Botox has no reason to travel to the rest of the body any way.

Timeline

Start
2016-01
Primary completion
2016-06
Completion
2017-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic Intramuscular

Indications